The Synthesis Core provides vital enabling technology for the Cystic Fibrosis Research and Translational Core Center. The Synthesis Core (Core D) has all of the equipment required for this effort and Prof. Kurth, the director of the Synthesis Core, has broad experience managing and implementing this equipment in targeted and library small molecule synthesis. The Synthesis Core interacts with Projects in the research base, providing three levels of service. Level I - the highest level of Synthesis Core service - constitutes concentrated involvement by the Synthesis Core in lead optimization and exploration of structure-activity relationships (SAR) by exhaustive synthesis. We anticipate that this level of involvement will continue for AF508-CFTR correctors / potentiators as well as for CaCC/TMEM16A activators. Depending on High- Throughput Screening (HTS) Core (Core A) discovery progress as well as the importance of focused chemistry in meeting Program goals, this level of involvement may also be warranted for other Projects. Level ll - the second level of Synthesis Core involvement - involves the resynthesis of lead compounds, provision of medicinal chemistry advice, and SAR analysis. Many Projects will benefit from this level of Synthesis Core service. Level 111 - the third level of service - requires minimal Synthesis Core effort and consists of providing compounds that have already been synthesized for Project studies as well as providing advice on the medicinal chemistry of active compounds. While individual Project needs will drive most of the Synthesis Core's activities, the Core will also interact with Cores A/B/C/E - primarily in providing any individual compounds needed for their work. The Synthesis Core will interact closely with the HTS Core to verify the identity of hits and validate hit activity by hit re-synthesis and spectroscopic characterization. All lead compounds supplied by the Synthesis Core for Project and Core activities will be highly purified (generally at -95%).

Public Health Relevance

The Synthesis Core provides vital enabling technology for the Cystic Fibrosis Research and Translational Core Center by providing three levels of service. Level I exhaustive synthesis applied to lead optimization and exploration of SAR. Level ll involves resynthesis of lead compounds, medchem advice, and SAR analysis. Level 111 consists of providing known compounds as well as medchem advice.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
5P30DK072517-08
Application #
8564923
Study Section
Special Emphasis Panel (ZDK1-GRB-W (M2))
Project Start
2012-06-01
Project End
2015-05-31
Budget Start
2012-06-01
Budget End
2013-05-31
Support Year
8
Fiscal Year
2012
Total Cost
$160,693
Indirect Cost
$48,922
Name
University of California San Francisco
Department
Type
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Sun, Dingyuan I; Tasca, Alexia; Haas, Maximilian et al. (2018) Na+/H+ Exchangers Are Required for the Development and Function of Vertebrate Mucociliary Epithelia. Cells Tissues Organs :1-14
Bhakta, Nirav R; Christenson, Stephanie A; Nerella, Srilaxmi et al. (2018) IFN-stimulated Gene Expression, Type 2 Inflammation, and Endoplasmic Reticulum Stress in Asthma. Am J Respir Crit Care Med 197:313-324
Smith, Alex J; Verkman, Alan S (2018) The ""glymphatic"" mechanism for solute clearance in Alzheimer's disease: game changer or unproven speculation? FASEB J 32:543-551
Duan, Tianjiao; Smith, Alex J; Verkman, Alan S (2018) Complement-dependent bystander injury to neurons in AQP4-IgG seropositive neuromyelitis optica. J Neuroinflammation 15:294
Lee, Sujin; Cil, Onur; Diez-Cecilia, Elena et al. (2018) Nanomolar-Potency 1,2,4-Triazoloquinoxaline Inhibitors of the Kidney Urea Transporter UT-A1. J Med Chem 61:3209-3217
Tradtrantip, Lukmanee; Felix, Christian M; Spirig, Rolf et al. (2018) Recombinant IgG1 Fc hexamers block cytotoxicity and pathological changes in experimental in vitro and rat models of neuromyelitis optica. Neuropharmacology 133:345-353
Phuan, Puay-Wah; Veit, Guido; Tan, Joseph-Anthony et al. (2018) ?F508-CFTR Modulator Screen Based on Cell Surface Targeting of a Chimeric Nucleotide Binding Domain 1 Reporter. SLAS Discov 23:823-831
Verkman, Alan S; Yao, Xiaoming; Smith, Alex J (2018) The evolving mystery of why skeletal muscle is spared in seropositive neuromyelitis optica. J Cell Mol Med 22:2039-2040
Verkman, Alan S; Tradtrantip, Lukmanee; Smith, Alex J et al. (2017) Aquaporin Water Channels and Hydrocephalus. Pediatr Neurosurg 52:409-416
Cil, Onur; Phuan, Puay-Wah; Gillespie, Anne Marie et al. (2017) Benzopyrimido-pyrrolo-oxazine-dione CFTR inhibitor (R)-BPO-27 for antisecretory therapy of diarrheas caused by bacterial enterotoxins. FASEB J 31:751-760

Showing the most recent 10 out of 276 publications